玻连蛋白血浆水平及基因多态性预测肺癌放疗后放射性肺炎
该前瞻性研究纳入165例接受胸部放疗的肺癌患者,检测放疗前血浆玻连蛋白(VTN)浓度并对其rs704和rs2227721位点进行基因分型。结果显示,VTN高血浆水平及特定基因型与≥3级放射性肺炎(RP)风险相关,联合平均肺剂量(MLD)与VTN浓度可将患者分为低、中、高风险组。
要点
- 放疗前血浆VTN水平≥132 μg/mL且MLD≥12 Gy的患者≥3级RP发生率为62.5%。
核心结论
- 放疗前较高的血浆VTN水平与更高的RP发生率相关,VTN rs704和rs2227721对预测RP风险均有显著作用。
- VTN浓度联合MLD有助于将接受放疗的肺癌患者分层为低、中、高风险RP组,VTN可能作为RP易感性的血液生物标志物。
研究设计与样本
- 前瞻性研究纳入165例接受放疗的肺癌患者,放疗前检测VTN浓度,采用Taqman探针法对VTN rs704和rs2227721进行基因分型。
- 采用Cox比例风险模型进行单因素和多因素分析以识别与RP风险相关的临床变量和基因型,用t检验和方差分析评估VTN表达水平。
主要发现
- rs704 AA基因型患者VTN水平高于GA/GG基因型患者。
关键数值与推荐
- VTN血浆水平临界值132 μg/mL,MLD临界值12 Gy,用于≥3级RP风险分层。
- 高风险:MLD≥12 Gy且VTN≥132 μg/mL,≥3级RP发生率62.5%(10/16)。
- 中风险:MLD≥12 Gy且VTN<132 μg/mL或MLD<12 Gy且VTN≥132 μg/mL,≥3级RP发生率11.4%(8/70)。
- 低风险:MLD<12 Gy且VTN<132 μg/mL,≥3级RP发生率1.3%(1/79)。
临床怎么用
- 放疗前可检测血浆VTN浓度及rs704、rs2227721基因型,联合MLD对肺癌放疗患者进行RP风险分层。
- 对高风险组(MLD≥12 Gy且VTN≥132 μg/mL)患者,可考虑加强RP监测与预防性干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our previous findings have identified vitronectin (VTN) as a potential biomarker for radiation pneumonitis (RP) through proteomics and molecular mechanism studies. In a recent study, we further explored associations of plasma level and single nucleotide polymorphisms of VTN with the risk of RP in patients with lung cancer receiving radiation therapy. METHODS AND MATERIALS: A total of 165 patients with lung cancer were prospectively enrolled with detection of VTN concentration before radiation therapy. VTN reference single nucleotide polymorphisms, rs704 and rs2227721, were genotyped by Taqman probe method. Cox proportional hazard models were performed to identify clinical variables and genotypes associated with the risk of RP on univariate and multivariate analyses, and t tests and analysis of variance were conducted to evaluate the expression level of VTN. RESULTS: The baseline secretion level of VTN in patients with grade ≥3 RP was significantly higher than that in grade <3 RP patients (P < .0001), and elevated levels were observed in patients having the AA genotype compared with GA/GG genotypes of rs704. The VTN rs704 GA/GG and rs2227721 AA/AC genotypes had a significantly lower risk of RP (hazard ratio [HR], 0.448, P = .005; HR, 0.419, P = .008, respectively). In addition, combining cut-off values of mean lung dose (MLD) and VTN plasma level, grade ≥3 RP risk groupings were as follows: high risk: MLD ≥12 Gy and VTN level ≥132 μg/mL (RP rate, 10 of 16 patients, 62.5%); intermediate risk: MLD ≥12 Gy and VTN level <132 μg/mL or MLD <12 Gy and VTN level ≥132 μg/mL (8 of 70 patients, 11.4%); and low risk: MLD <12 Gy and VTN level <132 μg/mL (1 of 79 patients, 1.3%) (P < .0001). CONCLUSIONS: Among patients receiving radiation therapy, relatively high plasma levels of VTN before radiation therapy were associated with the higher incidence of RP, and VTN rs704 and rs2227721 each had a significant effect on predicting RP risk. Combining VTN concentration with MLD appeared to facilitate stratification of patients with lung cancer who received radiation therapy into low-, intermediate-, and high-risk RP groups. This study indicated that VTN may serve as a blood biomarker for susceptibility to RP in patients with lung cancer.
引用
- Yu JH, Zhao QY, Liu Y, et al. The Plasma Levels and Polymorphisms of Vitronectin Predict Radiation Pneumonitis in Patients With Lung Cancer Receiving Thoracic Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33610390. doi:10.1016/j.ijrobp.2021.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。